ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2022 and some content may be unavailable. To unlock all content for 2022, please visit the archives.

Abstract: TH-PO550

Thrombo-Inflammatory Biomarkers of Cardiorenal Syndrome in ESRD

Session Information

  • Pathology and Lab Medicine
    November 03, 2022 | Location: Exhibit Hall, Orange County Convention Center‚ West Building
    Abstract Time: 10:00 AM - 12:00 PM

Category: Pathology and Lab Medicine

  • 1700 Pathology and Lab Medicine


  • Bansal, Vinod K., Loyola University Health System, Maywood, Illinois, United States
  • Karumanchi, Pranathi, Loyola University Health System, Maywood, Illinois, United States
  • Siddiqui, Fakiha, Loyola University Health System, Maywood, Illinois, United States
  • Jaradeh, Mark, Loyola University Health System, Maywood, Illinois, United States
  • Hoppensteadt, Debra, Loyola University Health System, Maywood, Illinois, United States
  • Fareed, Jawed, Loyola University Health System, Maywood, Illinois, United States

Cardiovascular complications commonly occur in patients with end-stage renal disease (ESRD) and lead to a 20-fold increase in mortality relative to the general population. The strong interdependence between ESRD and cardiovascular complications may be explained through cardiorenal syndrome (CRS). CRS comprises a spectrum of disorders involving both the heart and kidneys in which acute or chronic dysfunction in one organ may induce consequential pathogenesis in the other organ. Previous studies have demonstrated that inflammation and thrombosis are integral to CRS development and key cardiac and renal biomarkers are elevated in CRS patients. This study aims to profile thrombo-inflammatory biomarkers in ESRD patients to establish relevance to CRS.


Plasma samples were collected from 95 ESRD patients following approval by an IRB at Loyola University Medical Center. Control group was comprised of plasma samples (N=50), obtained from a commercial source (George King Biomedical, USA). Thrombo-inflammatory biomarkers, including Annexin V, MPO, Troponin, L-FABP, VEGF, D-dimer, TNF-alpha, IL-6, CRP, eNOS, Nitrotyrosine, MDA, NEFA, NO, vWF and MCP-1 were measured using commercially available ELISA methods. Results were compiled as group means±SEM and analyzed using GraphPad software.


Most of the biomarkers were significantly increased within the ESRD group compared to normal plasma. Annexin V (23.64%, p<0.001), L-FABP (1983%, p<0.0001), D-dimer (650.53%, p<0.0001), TNF-alpha (35.87%, p<0.0001), IL-6 (317.21%, p <0.0001), CRP (2214.43%, p<0.0001), NO (151.74%, p<0.0001), vWF (183.03%, p<0.0001), and MCP-1 (67.49%, p<0.0001) showed significant increase when compared to normal volunteers. Varying levels of correlations were noted within some of these biomarkers. Other measured biomarkers did not demonstrate any significant differences between the ESRD and control groups.


This study suggests that thrombo-inflammatory biomarkers may be helpful in the diagnosis of CRS in ESRD patients. This multi-parametric profiling may be helpful in risk stratification and prediction of adverse outcomes within ESRD patients and the development of CRS.


  • Private Foundation Support